Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

Authors

Keith W Pratz
Brian A Jonas
Vinod Pullarkat
Christian Recher
Andre C Schuh
Michael J Thirman
Jacqueline S Garcia
Courtney D DiNardo
Vladimir Vorobyev
Nicola S Fracchiolla
Su-Peng Yeh
Jun Ho Jang
Muhit Ozcan
Kazuhito Yamamoto
Arpad Illes
Ying Zhou
Monique Dail
Brenda Chyla
Jalaja Potluri
Hartmut Döhner

Publication Date

3-10-2022

Journal

Journal of Clinical Oncology

Abstract

PURPOSE: There is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete remission (CRc; complete remission + complete remission with incomplete hematologic recovery) and MRD < 10

METHODS: The patients included in this report were treated with venetoclax and azacitidine. Bone marrow aspirate samples for multiparametric flow cytometry assessments were collected for central analysis at baseline, end of cycle 1, and every three cycles thereafter. MRD-negative response was defined as < 1 residual blast per 1,000 leukocytes (< 10

RESULTS: One hundred sixty-four of one hundred ninety (86%) patients with CRc were evaluable for MRD. MRD < 10

CONCLUSION: Patients who achieved CRc and MRD < 10

Keywords

Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Humans, Leukemia, Myeloid, Acute, Neoplasm, Residual, Prognosis, Remission Induction, Sulfonamides

DOI

10.1200/JCO.21.01546

PMID

34910556

PMCID

PMC8906463

PubMedCentral® Posted Date

12-15-2021

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes